WO2006054312A1 - Composé de type ammonium pour le traitement de psoriasis et d'eczéma - Google Patents

Composé de type ammonium pour le traitement de psoriasis et d'eczéma Download PDF

Info

Publication number
WO2006054312A1
WO2006054312A1 PCT/IN2004/000354 IN2004000354W WO2006054312A1 WO 2006054312 A1 WO2006054312 A1 WO 2006054312A1 IN 2004000354 W IN2004000354 W IN 2004000354W WO 2006054312 A1 WO2006054312 A1 WO 2006054312A1
Authority
WO
WIPO (PCT)
Prior art keywords
ammonium
eczema
composition
psoriasis
ammonia
Prior art date
Application number
PCT/IN2004/000354
Other languages
English (en)
Inventor
Munisekhar Medasani
Original Assignee
Munisekhar Medasani
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Munisekhar Medasani filed Critical Munisekhar Medasani
Priority to PCT/IN2004/000354 priority Critical patent/WO2006054312A1/fr
Publication of WO2006054312A1 publication Critical patent/WO2006054312A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline

Definitions

  • the present invention details the properties and administration of Ammonium Compounds in treating the Psoriasis and other related skin disorders and diseases. More particularly this invention pertains to ammonium compounds used as a active ingredients in preparation of a composition for administration for prevention, reduction, relief, treat or cure Psoriasis, Eczema and other related skin disorders and diseases.
  • Allergens are substances from foods, plants, environment or animals that inflame the skin because the immune system over-reacts to these substances. Inflammation occurs even when the person is exposed to very small amounts of the substance for a limited period of time.
  • Some examples of allergens are pollen and pet's dander (tiny particles from the animal's skin or hair).
  • Allergic reactions are classified into from type I to type IV depending on the causative immunoglobulins and cells participating therein.
  • the types I to III allergies are immunological reactions in which human antibodies participate. They are called immediate-type allergies, since allergic reactions appear immediately upon contact.
  • the type IV allergy is a cell-mediated immunological reaction in which instead of an antibody, sensitized lymphocytes participate. It is also called delayed-type allergy.
  • Allergic reaction of type IV is a reaction of a delayed type in which T cells (small white blood cells that orchestrate and/or directly participate in the immune defenses, also known as T lymphocytes) receiving an antigen information via antigen-presenting cells and release various cytokines whereby an inflammation reaction of a delayed type takes place.
  • Allergic dermatitis is a typical disease, which occurs due to an allergic reaction of type IV.
  • Steroid compositions are used for the therapy of allergic diseases of type IV and such steroid compositions suppress the production of cytokine in T cells and show a -dramatic effect for the therapy of eczema.
  • cytokine in T cells
  • eczema a -dramatic effect for the therapy of eczema.
  • severe adverse actions such as thinning/ sensitizing of skin, sleeplessness, photosensitivity, decrease in adrenocortical function etc. by long period administration.
  • psoriasis An example of an allergic and immunology mediated skin disease is psoriasis.
  • psoriasis is like a disorder of the immune system.
  • This system includes a type of white blood cell, called as T cell that normally helps protect the body against infection and disease.
  • T cell white blood cell
  • T cells that normally helps protect the body against infection and disease.
  • Many of the pathological and histological findings of this disease are equivalent to those of dermatitis (eczema).
  • Psoriasis is frequently worsened and becomes chronic by external stimulus. In each case, it is the fundamental therapy to control the skin symptoms to thereby prevent worsening.
  • Psoriasis treatments for Psoriasis are corticosteroids, calcipotriene, anthralin, topical retinoid, coal tar, salicylic acid and new generation biological drugs. All of these treatments have side effects and become ineffective when used in for long period of time or suppress over all immunity of the body.
  • Ammonium compounds are being used presently in the cleansing liquids etc, but it has not been used as an ingredient specifically to provide a therapy for prevention, reduction and relief of scaling of allergic and/or autoimmune skin disorders.
  • ammonium chloride ammonia other ammonium salts and other . quarternary ammonium compounds such as ammonium laureth sulfate, benzalkonium chloride, benzethonium chloride, cetalkonium chloride, cetrimide, cetrimonium bromide, cetylpyridinium chloride, glycidyl trimethyl, stearalkonium chloride, and the like can be used to like effect.
  • Ammonium Salts/compounds are as food additive, disinfectants, in cough syrups, eye drops, urine acidifiers etc and ammonia in hair coloring agents, but it is not been used for treating or relief of psoriasis and eczema like skin disorders.
  • the present invention details the properties and administration of Ammonia or Ammonium Salts or Ammonium Compounds in treating the Psoriasis, Eczema and other related skin disorders.
  • the present invention also relates to a pharmaceutical composition as well as pharmaceutical and/or cosmetic preparation containing Ammonia or Ammonium Salt or Ammonium compounds as an effective and/or active ingredient and, more particularly, it relates topical preparation having an action of keratolytic and/or suppressing the immediate-type and delayed-type allergy and/or reducing inflammation, to a pharmaceutical composition with an object of improving the allergy and to a cosmetic composition containing the same.
  • This invention provides a therapy for prevention, reduction and relief of scaling of allergic and/or autoimmune skin diseases, such as psoriasis, pityriasis rosea, lichen planus, pityriasis rubra pilaris, dermatitis (eczema), acne, dandruff etc, which has no adverse ⁇ action, shows a high safety even by administration for a long period and is able to be utilized as pharmaceutical and/or cosmetics, etc. which are used daily.
  • allergic and/or autoimmune skin diseases such as psoriasis, pityriasis rosea, lichen planus, pityriasis rubra pilaris, dermatitis (eczema), acne, dandruff etc, which has no adverse ⁇ action, shows a high safety even by administration for a long period and is able to be utilized as pharmaceutical and/or cosmetics, etc. which are used daily.
  • topical application provides keratolytic effect with anti-allergic and anti-inflammatory effect and it is characterized in containing Ammonia or Ammonium Salts or Ammonium Compounds as an effective and/or active ingredient; an anti-allergic composition for topical administration or an anti ⁇ inflammatory composition for topical administration which is characterized in containing Ammonia or Ammonium Salts or Ammonium Compounds as an effective and/or active ingredient to pharmaceutical and/or cosmetic preparation for it is useful in preventing, reducing or relieving allergic symptoms and/or inflammatory symptoms of psoriasis, Eczema and like skin disorders and diseases.
  • This invention provides a therapeutic and preventive composition for allergic and immunology skin diseases which has no adverse action, shows a high safety even by a long-term administration and is able to be utilized for pharmaceutical and/or cosmetic preparation and cosmetic composition which are used daily.
  • Ammonium chloride is being used presently in the cleansing liquids etc, but it has not been used as an ingredient specifically to provide a therapy for prevention, reduction and relief of scaling of allergic and/or autoimmune skin diseases.
  • ammonium ' chloride ammonia and other quartemary ammonium compounds, such as benzalkonium chloride, benzethonium chloride, cetalkonium chloride, cetrimide, cetrimonium bromide, cetylpyridinium chloride, glycidyl trimethyl, stearalkonium chloride, and the like can be used to like effect.
  • composition qontaining ammonium chloride and/or ammonium surfactants and/or quarternary ammonium compounds exhibited therapeutic property in treating psoriasis-affected patients.
  • composition exhibited better results when moisturizing natural extracts and/or oils like chamomile, sunflower, coconut etc are used in the composition preparation.
  • the above solution was poured into a mortar and mixed thoroughly with pestle to get uniform mixture and checked the pH and adjusted to 5-6 by adding buffering agent. When the temperature reaches to 40°c a few drops of Vanilla extract, Chamomile Extract, fragrance and a pinch of color is added. The mixture was slowly cooled to room temperature. The shampoo was packed in to clean plastic tins.
  • the above solution was poured into a mortar and mixed thoroughly with pestle to get uniform mixture and checked the pH and adjusted to 5-6 by adding buffering agent. When the temperature reaches to 40°c a few drops of Vanilla extract, Chamomile Extract, fragrance and a pinch of color is added The mixture was slowly cooled to room temperature. The shampoo was packed in to clean plastic tins.
  • vanilla extract 1 gm Lye water and vegetable oil were heated to 35 deg. C and mixed in a stainless steel pot with wooden stirrer. Heated the mixture with continued stirring to boil till mass turned to light caramel. The mass was tested by proving method. Kept the boiling continued till th froth settled down. And checked the doneness. Graining was done with potassium chloride and ammonium chloride. Cooled the mass and skimmed. Remelted the mass and added the vanilla extract while stirring. Poured the mass into the moulds and allowed to set and harden for 24 hrs. Taken out the harden bars from the moulds and cut into small pieces. The pieces were air dried for 20 days and used.
  • This invention is lead by desire for developing a new and innovative treatment, which can be used in the longer periods of time without side effect associated with other products.
  • the Topical Composition given in the example being used for more than 6 months and also tested on other psoriasis patients with encouraging results.
  • compositions are convenient to use, cost effective compared to other preparations and most of all these can be used for longer periods of time without side effects.
  • the responsive time to the treatment may be different for each individual patient and depends upon the severity of the lesions. Typically some improvement is visible after 3-4 days after initiation of treatment.
  • ammonia/ammonium salts/ quaternary ammonium compounds such as ammonium chloride

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention a pour objet l’administration de composés de type ammonium au titre de composants actifs et efficaces dont les propriétés sont liées à la prévention, la réduction, le soulagement et le traitement du Psoriasis ou de l’Eczéma et d’autres maladies de ce type. La présente invention a également pour objet l’administration desdits composés par application locale ou transdermique.
PCT/IN2004/000354 2004-11-16 2004-11-16 Composé de type ammonium pour le traitement de psoriasis et d'eczéma WO2006054312A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/IN2004/000354 WO2006054312A1 (fr) 2004-11-16 2004-11-16 Composé de type ammonium pour le traitement de psoriasis et d'eczéma

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2004/000354 WO2006054312A1 (fr) 2004-11-16 2004-11-16 Composé de type ammonium pour le traitement de psoriasis et d'eczéma

Publications (1)

Publication Number Publication Date
WO2006054312A1 true WO2006054312A1 (fr) 2006-05-26

Family

ID=36406872

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2004/000354 WO2006054312A1 (fr) 2004-11-16 2004-11-16 Composé de type ammonium pour le traitement de psoriasis et d'eczéma

Country Status (1)

Country Link
WO (1) WO2006054312A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017146602A1 (fr) * 2016-02-24 2017-08-31 Arcasiu Nicolae Sels de chlore ou de brome de cétylpyridinium pour utilisation dans le traitement de porphyries cutanées et aiguës et du psoriasis
US10835584B2 (en) * 2016-06-17 2020-11-17 Nuvothera, Inc. Systems for treating dermal inflammatory conditions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000010556A1 (fr) * 1998-08-19 2000-03-02 Beiersdorf Ag Utilisation de composes azotes quaternaires pour la prophylaxie et le traitement de l'eczema atopique surinfecte
WO2001010427A2 (fr) * 1999-08-09 2001-02-15 Arakis Limited Utilisation topique d'agents anti-muscarinique
WO2004022022A1 (fr) * 2002-09-03 2004-03-18 Jerzy Hubert Edward Dangel Composition topique pour traiter des troubles cutanes
WO2004084855A1 (fr) * 2003-03-27 2004-10-07 Medasani Munisekhar Composition keratolique aux proprietes anti-inflammatoires et anti-allergiques

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000010556A1 (fr) * 1998-08-19 2000-03-02 Beiersdorf Ag Utilisation de composes azotes quaternaires pour la prophylaxie et le traitement de l'eczema atopique surinfecte
WO2001010427A2 (fr) * 1999-08-09 2001-02-15 Arakis Limited Utilisation topique d'agents anti-muscarinique
WO2004022022A1 (fr) * 2002-09-03 2004-03-18 Jerzy Hubert Edward Dangel Composition topique pour traiter des troubles cutanes
WO2004084855A1 (fr) * 2003-03-27 2004-10-07 Medasani Munisekhar Composition keratolique aux proprietes anti-inflammatoires et anti-allergiques

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017146602A1 (fr) * 2016-02-24 2017-08-31 Arcasiu Nicolae Sels de chlore ou de brome de cétylpyridinium pour utilisation dans le traitement de porphyries cutanées et aiguës et du psoriasis
US20190000822A1 (en) * 2016-02-24 2019-01-03 Nicolae Arcasiu Chlorine or bromine salts of cetylpyridinium for use in the treatment of cutaneous and acute porphyrias and psoriasis
US10835584B2 (en) * 2016-06-17 2020-11-17 Nuvothera, Inc. Systems for treating dermal inflammatory conditions
US11590211B2 (en) 2016-06-17 2023-02-28 Nuvothera, Inc. Systems for treating dermal inflammatory conditions

Similar Documents

Publication Publication Date Title
US10179148B2 (en) Keratolytic composition with anti-allergic anti-inflammatory properties
ES2234083T3 (es) Utilizacion de un extracto de al menos un vegetal de la familia de las rosaceas.
WO2017103936A1 (fr) Préparations de soin de la peau pour bébés
CN113041172A (zh) 用于肌肤屏障修护的皮脂膜仿生组合物及其应用和化妆品
CN103385832A (zh) 一种以薰衣草提取物为主要活性成分的抗衰老化妆品
KR20000046633A (ko) 아토피성 피부염 치유용 조성물
WO2017111069A1 (fr) Agent antiprurigineux
JP2006321758A (ja) 化粧品
WO2006054312A1 (fr) Composé de type ammonium pour le traitement de psoriasis et d'eczéma
Slade et al. Clinical efficacy evaluation of a novel barrier protection cream
KR20190092822A (ko) 압타민 c를 유효성분으로 포함하는 피부질환 개선 및 치료용 조성물
WO2009145654A1 (fr) Préparation de soin et de protection de la peau pour enfants et adultes et son procédé d'obtention
WO2019162788A1 (fr) Composition destinée à être utilisée dans le traitement de la dermatite séborrhéique
RU2813104C1 (ru) Средство для лечения алопеции на основе четвертичного аммониевого соединения, содержащего фрагмент пиридоксина
JP2003055191A (ja) アトピー性皮膚炎及び各種の乾皮症、荒れ肌症用スキンケア・治療外用製剤
JP2005015375A (ja) Ａｌｔｅｒｏｍｏｎａｓｍａｃｌｅｏｄｉｉから得られる外分泌性ポリサッカライドを含有することを特徴とする皮膚外用剤
Belsito et al. Safety Assessment of Charcoal Ingredients as Used in Cosmetics
RU2426540C1 (ru) Противовоспалительное и противоаллергическое лекарственное средство и фармацевтическая композиция на его основе
KR20210037338A (ko) 피부진정과 아토피 개선용 인퓨즈드 오일의 제조방법
NL2018299B1 (nl) Samenstelling voor toepassing in de behandeling van een huidaandoening
KR20020048211A (ko) 아토피성 피부염으로 인한 건조함으로부터 피부를보호하기 위한 조성물
WO2013045031A1 (fr) Composition à appliquer sur la peau, et son utilisation
KR20230038964A (ko) 여드름 원인균 프로피오니박테리움 아크네스에 대한 항균성 무자극 피부 외용제 조성물
WO2020022989A2 (fr) Compositions topiques pour soins de peau de bébé
KR101747699B1 (ko) 세포간 간극 결합 차단 물질을 함유하는 피부 진정 또는 자극 완화용 화장료 조성물

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 04806750

Country of ref document: EP

Kind code of ref document: A1